Download Files:
Products Details
Product Description
– GW3965 is a potent, selective liver X receptor (LXR) agonist with EC50s of 190 nM and 30 nM for hLXRα and hLXRβ, respectively[1][2][3].
Web ID
– HY-10627
Shipping
– Room temperature
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C33H31ClF3NO3
Citations
– Am J Physiol Endocrinol Metab. 2019 Jun 1;316(6):E1136-E1145. |Bioconjug Chem. 2015 Nov 18;26(11):2216-22. |Cancer Lett. 2023 May 5;216208.|Cell Death Differ. 2020 Aug;27(8):2433-2450. |J Am Heart Assoc. 2021 May 8;e018455.|J Ethnopharmacol. 2023 May 24;315:116684.|Sci Adv. 15 Jul 2022.|Theranostics. 2020 Jul 11;10(19):8834-8850. |bioRxiv. 2023 Mar 10.|Radboud University Nijmegen. 2021 Mar.|Viruses. 2022, 14(3), 514.
References
– [1]Guo, Deliang., et al. An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR-Dependent Pathway. Cancer Discovery (2011), 1(5), 442-456.|[2]Mitro, Nico., et al. LXR and TSPO as new therapeutic targets to increase the levels of neuroactive steroids in the central nervous system of diabetic animals. Neurochemistry International (2012), 60(6), 616-621.|[3]Spyridon, Michael., et al. LXR as a novel antithrombotic target. Blood (2011), 117(21), 5751-5761.
CAS Number
– 405911-09-3
Molecular Weight
– 582.05
SMILES
– ClC1=C(C(F)(F)F)C=CC=C1CN(CC(C2=CC=CC=C2)C3=CC=CC=C3)CCCOC4=CC(CC(O)=O)=CC=C4
Clinical Information
– No Development Reported
Research Area
– Cardiovascular Disease
Solubility
– 10 mM in DMSO
Target
– LXR
Pathway
– Metabolic Enzyme/Protease;Vitamin D Related/Nuclear Receptor
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
